Most Popular
-
6
[Graphic News] More Koreans say they plan long-distance trips this year
![[Graphic News] More Koreans say they plan long-distance trips this year](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/17/20240417050828_0.gif&u=)
-
7
[KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs
![[KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/18/20240418050645_0.jpg&u=20240419100350)
-
8
North Korea removes streetlights along cross-border roads with South
-
9
Russia's denial of entry of S. Korean national unrelated to bilateral ties: Seoul official
-
10
Farming households dip below 1m for first time in 2023
![[Graphic News] More Koreans say they plan long-distance trips this year](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/17/20240417050828_0.gif&u=)
![[KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/18/20240418050645_0.jpg&u=20240419100350)
Samsung Biologics said Monday it has signed a contract to develop PharmAbcine’s anti-cancer and angiogenesis material PMC-402.
The South Korean firm will provide all-step CDO support from cell line development to clinical sample manufacturing and investigational new drug application, as well as produce preclinical and global clinical trial materials.
PMC-402, according to PharmAbcine, helps normalize newly formed abnormal blood vessels that feed the growth of tumors, or the condition called angiogenesis.
Yoo Jin-san, president and CEO of PharmAbcine, said that the anti-cancer qualities of PMC-402 was proven in independent research and in combination with immuno-oncology drugs.
The drug has potential to have therapeutic effects for ophthalmological malconditions such as diabetic retinopathy and age-related macular degeneration.
PharmAbcine plans to enter global phase 1 clinical trials from 2021.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
The South Korean firm will provide all-step CDO support from cell line development to clinical sample manufacturing and investigational new drug application, as well as produce preclinical and global clinical trial materials.
PMC-402, according to PharmAbcine, helps normalize newly formed abnormal blood vessels that feed the growth of tumors, or the condition called angiogenesis.
Yoo Jin-san, president and CEO of PharmAbcine, said that the anti-cancer qualities of PMC-402 was proven in independent research and in combination with immuno-oncology drugs.
The drug has potential to have therapeutic effects for ophthalmological malconditions such as diabetic retinopathy and age-related macular degeneration.
PharmAbcine plans to enter global phase 1 clinical trials from 2021.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
![[From the Scene] Monks, Buddhists hail return of remains of Buddhas](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/19/20240419050617_0.jpg&u=20240419175937)
![[KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/18/20240418050645_0.jpg&u=20240419100350)
![[Today’s K-pop] Illit drops debut single remix](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=642&simg=/content/image/2024/04/19/20240419050612_0.jpg&u=)